Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
https://www.fool.com/investing/2024/04/05/got-5000-these-3-high-yielding-dividend-stocks-are/?source=iedfolrf0000001
Apr 05, 2024 - All of these stocks pay generous dividends that income investors will appreciate.
0
The AI Race Gets Litigious
https://www.fool.com/investing/2024/03/09/the-ai-race-gets-litigious/?source=iedfolrf0000001
Mar 09, 2024 - We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
0
Top Research Reports for Merck, ServiceNow & Blackstone
https://www.zacks.com/commentary/2228528/top-research-reports-for-merck-servicenow-blackstone?cid=CS-ZC-FT-research_daily-2228528
Feb 20, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), ServiceNow, Inc. (NOW) and Blackstone Inc. (BX).
0
Where Are Biotech ETFs Headed After Q4 Earnings?
https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390
Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
0
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414
Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
0
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529
Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
0
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
https://www.zacks.com/stock/news/2222190/gilead-gild-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2222190
Feb 06, 2024 - The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More
https://www.zacks.com/stock/news/2222125/late-session-earnings-bonanza-ford-chipotle-snap-more?cid=CS-ZC-FT-ahead_of_wall_street-2222125
Feb 06, 2024 - Markets bounced back this Tuesday from a Monday sell-off, though not all the way back to Friday highs.
0
Earnings Data Deluge
https://www.zacks.com/stock/news/2221920/earnings-data-deluge?cid=CS-ZC-FT-economic_highlights-2221920
Feb 06, 2024 - Earnings Data Deluge.
0
Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More
https://www.zacks.com/stock/news/2221113/drug-biotech-stocks-q4-earnings-due-on-feb-6-amgn-lly-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2221113
Feb 05, 2024 - Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
0
Pages: 12
Page 1